Contraceptive eligibility for women at high risk of HIV: Guidance statement

WHO

The World Health Organization (WHO) convened a Guideline Development Group (GDG) meeting from 29 to 31 July 2019 to review global guidance on contraceptive eligibility for women at high risk of HIV acquisition to and determine whether revisions to the fifth edition of the Medical eligibility criteria for contraceptive use (MEC) were needed. The issue was deemed critical, particularly for sub-Saharan Africa, given the high lifetime risk of acquiring HIV alongside the importance of hormonal contraception in offering women and adolescent girls’ choice and in reducing their risk of unintended pregnancy, a common threat to the health, well-being and lives of women and adolescent girls.

The GDG consisted of 28 participants from 19 countries, including experts in family planning and HIV, representatives from affected populations, clinicians, epidemiologists, researchers, programme managers, policy-makers and guideline methodologists.

September 2, 2019
Year of publication
2019
Resource types
Guidelines and Policies, Programmatic guidance
Tags
hormonal contraception, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study, ECHO study, depot-medroxyprogesterone acetate (DMPA), Depo-Provera, WHO guidelines, Medical eligibility criteria for contraceptive use (MEC)

Similar Resources

Multipurpose prevention technologies (MPTs) are preferably single dosage forms designed to simultaneously address multiple sexual and reproductive health needs, such as unintended pregnancy, HIV infection and other sexually transmitted infections (STIs).

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.

This paper documents the development of the global and national monitoring and reporting systems for PMTCT and paediatric HIV care and treatment programmes, achievements and remaining challenges.

The starting point for this guideline is the point at which a woman has learnt that she is living with HIV, and it therefore covers key issues for providing comprehensive sexual and reproductive health and rights-related services and support for women living with HIV.

The HER campaign is a collaborative platform for diverse partners to support adolescent girls and young women in countries with a high risk of HIV.

HIV affects more women than any other life-threatening infectious agent, and most infections are sexually transmitted.

An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.

HIV acquisition during pregnancy and breastfeeding significantly contributes toward paediatric HIV infection; however, little is known about risk behaviours in HIV-uninfected pregnant and postpartum women.

End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy.